Page tree

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

View file
name2017-02-17-EAG-Update.ppt.pptx
height250

Date

02/17/2017

 1900-2100 UTC 

GoToMeeting Details

SNOMED Int'l Editorial Advisory group  

Fri, Feb 17, 2017 11:00 AM - 1:00 PM PST

Please join my meeting from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/724143757

You can also dial in using your phone.
Denmark (Toll Free): 8025 3112
United States: +1 (669) 224-3318

Access Code: 724-143-757

More phone numbers
Australia: +61 2 9091 7603
Belgium: +32 (0) 27 00 6375
Canada: +1 (647) 497-9373
Denmark: +45 43 31 47 79
Netherlands: +31 (0) 707 709 520
New Zealand: +64 9 913 2226
Spain: +34 912 71 8488
Sweden: +46 (0) 853 527 818
United Kingdom: +44 (0) 20 3713 5011

First GoToMeeting? Try a test session: http://help.citrix.com/getready

Meeting Files

 

View file
nameRelationship group zero.pptx
height250

View file
nameReview of SNOMED CT models for representing allergic conditions.docx
height250
View file
nameEAG meeting Feb_17_2017.pptx
height250

View file
nameProposal to create Dispositions - EAG v0.1.docx
height250

Objectives

  • Obtain consensus on agenda items

Discussion items

ItemDescriptionOwnerNotesAction
1Call to order and role callJCA 

Paul Amos communicated that he would not be able to make the call.

 

2Conflicts of interestJCANone. 
3Approval of minutes from 01/20/2017JCA As of the start of the meeting quorum did not exist. Could not approve

 

4Drug Model deliverable reviewTMODrug Model Editorial Guide 
5Substance redesign document reviewJCA/TMO

Substance hierarchy redesign

Substance disposition proposal (see attached document)

 

6Guidance for creation of new anatomy conceptsJCA

Issue: In some cases, the representation of FINDING SITE at the proper level of granularity requires multiple body structures. E.g.:

The proposal under consideration is:

"If two body structures are needed to fully define the finding site for a condition, then a combined anatomic structure shall be created to represent that body structure."

For example: A new body structure "Bone structure of distal phalanx of great toe (body structure)" would be created to support the modeling of the concept above.

 
7Editorial guidance on role groupingJCA

Create a table of mandatory grouping of relationships.  Rationale – needed for template based authoring, provides internal consistency of model patterns, allows for batch editing due to consistency.

See initial review from Daniel Karlsson and Yongshen Gao

 
8"X in remission"JCA

Existing tracker: "In remission" disorders

Hold over item from initial meeting in Uruguay. Has been brought up again with a large number of requests for addition of "X in remission" concepts.

Existing Inception document: Modeling "disease in remission"

Document definition: "The period in the course of a disease/condition during which there is temporary lessening or abatement of signs and/or symptoms of the disease."

Based on historical view of "Disease in remission" there are some assumptions:

  1. The disease condition is still present.
  2. The disease is chronic and/or progressive

Prior proposals:

  • Model as situations with the reactivation of 278174000 | Disease phase (attribute) | with allowed values >303105007 | Disease phases (qualifier value) | with necessary changes to this set to align with standard representation of disease phases
  • Leave the concepts in the disorder hierarchy and create a new attribute such as disease activity and include as its range, qualifier values that specifically represent disease activities such as remission, recurrent, relapsing, active, relapsing/remitting, etc.
  • Model disorder X in remission as a child of disorder X and a child of disorder in remission (the latter as a replacement for patient in remission).
  • Extend the set of values under "Courses" to include disease phases and model "Disease in remission" as a subtype of "Disease"

One related issue is the current overlap of concepts under "Courses" and "Disease phases".

Challenge is that disease phases differ with the "type" of disease.

  • Infectious disease
  • Malignant disease
  • Mental an behavioral disorders

Question: Pros and cons of creating type specific phases?

The result of this discussion should be extensible to other patterns of "Disease in X" (e.g. latent disease, relapse, etc.) for which there are several CRS requests outstanding.

Related issue: IHTSDO-407 Frequencies and Courses

 
9Extension of range of SPECIMEN SUBSTANCE to physical objectJCA

Initially discussed in Uruguay, postponed to future meeting

Existing tracker item: IHTSDO-604 Extend the range of "Specimen substance"

Use cases:

  • Physical object as a specimen for environmental and epidemiologcal testing
  • Pharmaceutical/biological products as specimens for sterility and quality assurance

Earlier discussion points:

  • "Device specimen" already allowed and fully defined but uses SPECIMEN SOURCE IDENTITY as the defining relationship. This scenario may work if the range for SPECIMEN SOURCE IDENTITY is extended to Physical object (<)
 
10ECE UpdateBGO

Update on ongoing issues with ECE

 

 

11Aligning SNOMED CT with clinical use casesKCA/JCACarried over from past meetings: High level discussion on whether SNOMED CT is appropriately organized to support the highly variable granularity of content the are influenced by current EHR applications (i.e. single code recording of pre-coordinated content) and newer initiatives that are focused on capturing more structured data (e.g. CIMI, FHIR) 
12Next meetingEAG